Can You Take Progesterone 100 mg and Veozah Together?
Yes, progesterone 100 mg and Veozah (fezolinetant) can be taken together safely, as there are no known drug interactions or contraindications between these medications. Veozah is a non-hormonal neurokinin-3 receptor antagonist that works through a completely different mechanism than progesterone, targeting the hypothalamic thermoregulatory center rather than hormonal pathways 1, 2.
Key Clinical Considerations
Why This Combination May Be Used
Women taking progesterone 100 mg typically have an intact uterus and are using it for:
- Endometrial protection when taking estrogen therapy
- Management of menopausal symptoms
- Other gynecologic indications
Veozah is prescribed specifically for moderate-to-severe vasomotor symptoms (hot flashes and night sweats) and represents a non-hormonal alternative when hormone therapy alone is insufficient or when additional symptom control is needed 1, 2.
Safety Profile of Each Medication
Veozah (Fezolinetant):
- Demonstrated safety over 52 weeks in multiple phase 3 trials involving over 3,000 women 1, 2
- Most common side effects: upper respiratory tract infection (7.7-8.3%), headache (6.8-8.2%), back pain, and diarrhea 2
- Critical monitoring requirement: Liver function tests must be performed before starting, at months 3,6, and 9, then periodically thereafter, as 1.5-2.3% of patients experience transaminase elevations 2
- No endometrial safety concerns (endometrial hyperplasia rate 0.5% with upper CI limit of 2.3%, well within FDA safety criteria) 1
Progesterone 100 mg:
- Standard dose for endometrial protection when used with estrogen 3
- Contraindications include known hypersensitivity (contains peanut oil), undiagnosed vaginal bleeding, breast cancer history, active thromboembolism, and liver disease 3
No Pharmacologic Interaction
These medications work through entirely separate pathways:
- Progesterone: Acts on progesterone receptors in target tissues
- Veozah: Blocks neurokinin-3 receptors in the hypothalamus to reduce vasomotor symptoms
There is no evidence of drug-drug interactions, metabolic interference, or additive toxicity between these agents 1, 2, 4.
Clinical Algorithm for Combined Use
Step 1: Verify Progesterone Indications
- Confirm patient has intact uterus requiring endometrial protection
- Rule out progesterone contraindications (particularly liver disease, as both medications require liver monitoring) 3
Step 2: Assess Veozah Candidacy
- Confirm moderate-to-severe vasomotor symptoms inadequately controlled by current therapy
- Obtain baseline liver function tests (ALT, AST, total bilirubin) before initiating Veozah 2
- Ensure no active liver disease
Step 3: Initiate or Continue Combined Therapy
- Progesterone 100 mg: typically given once daily in evening or 100 mg AM/200 mg PM dosing 5
- Veozah: 45 mg once daily (standard dose for vasomotor symptoms) 1, 2
Step 4: Mandatory Monitoring
- Liver function tests at months 3,6, and 9 after starting Veozah, then periodically 2
- If ALT/AST >3× upper limit of normal, discontinue Veozah and monitor until resolution
- Continue routine monitoring appropriate for progesterone therapy
Important Caveats
Real-world utilization data shows:
- Only 42% of persistent Veozah users received appropriate liver function monitoring within 3 months of initiation 6
- Do not skip liver monitoring—this is a critical safety requirement
Special populations:
- 20.5% of real-world Veozah users had breast cancer history 6
- Both medications can be used in breast cancer survivors (Veozah is non-hormonal; progesterone alone without estrogen has different risk profile than combined hormone therapy) 7
Duration considerations:
- Veozah has been studied for safety up to 52 weeks 1, 2, 4
- Progesterone duration depends on whether estrogen is being used concurrently and individual risk factors
The combination is pharmacologically sound and clinically appropriate when both medications are indicated for their respective purposes, provided mandatory liver monitoring for Veozah is performed.